State Street Corp Immuneering Corp Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Immuneering Corp stock. As of the latest transaction made, State Street Corp holds 376,896 shares of IMRX stock, worth $538,961. This represents 0.0% of its overall portfolio holdings.

Number of Shares

376,896

Previous 373,662 0.87%

Holding current value

$538,961

Previous $2.75 Million 60.34%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.91 - $7.32 $6,176 - $23,672	3,234 Added 0.87%	376,896 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$4.84 - $8.44 $59,851 - $104,369	12,366 Added 3.42%	373,662 $2.75 Million
Q3 2023 Nov 14, 2023	BUY	$7.21 - $10.68 $199,529 - $295,558	27,674 Added 8.3%	361,296 $2.77 Million
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $1.82 Million - $3.74 Million	279,887 Added 520.87%	333,622 $3.38 Million
Q1 2023 May 15, 2023	SELL	$3.78 - $10.38 $1,134 - $3,114	-300 Reduced 0.56%	53,735 $521,000

Q4 2022 Feb 14, 2023	BUY	$4.09 - $10.24 $101,841 - $254,976	24,900 Added 85.46%	54,035 $262,000
Q3 2022 Nov 15, 2022	BUY	$5.0 - $12.85 $20,500 - $52,685	4,100 Added 16.38%	29,135 $417,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $589,121 - $1.18 Million	-151,445 Reduced 85.81%	25,035 $135,000
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $365,807 - $960,597	56,539 Added 47.14%	176,480 $1.14 Million
Q4 2021 Feb 14, 2022	BUY	$16.12 - $31.02 $302,072 - $581,283	18,739 Added 18.52%	119,941 $1.94 Million
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $1.72 Million - $3.32 Million	101,202 New	101,202 $2.69 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $37.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Immuneering Corp Transaction History